CoChat
Sign Up
Cited by 704

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Current concepts in the pathophysiology and treatment of aplastic anemia

Young, Neal S., Calado, Rodrigo T., Scheinberg, Phillip·2006·Blood
DOI 10.1182/blood-2006-03-010777
Open this paper in CoChat — free account

Abstract

Aplastic anemia, an unusual hematologic disease, is the paradigm of the human bone marrow failure syndromes. Almost universally fatal just a few decades ago, aplastic anemia can now be cured or ameliorated by stem-cell transplantation or immunosuppressive drug therapy. The pathophysiology is immune mediated in most cases, with activated type 1 cytotoxic T cells implicated. The molecular basis of the aberrant immune response and deficiencies in hematopoietic cells is now being defined genetically; examples are telomere repair gene mutations in the target cells and dysregulated T-cell activation pathways. Immunosuppression with antithymocyte globulins and cyclosporine is effective at restoring blood-cell production in the majority of patients, but relapse and especially evolution of clonal hematologic diseases remain problematic. Allogeneic stem-cell transplant from histocompatible sibling donors is curative in the great majority of young patients with severe aplastic anemia; the major challenges are extending the benefits of transplantation to patients who are older or who lack family donors. Recent results with alternative sources of stem cells and a variety of conditioning regimens to achieve their engraftment have been promising, with survival in small pediatric case series rivaling conventional transplantation results.

Overview

Integrity signals

Registry

Crossref · 10.1182/blood-2006-03-010777

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 123

  1. Young NS. Aplastic anemia. In: Young NS, ed. The Bone Marrow Failure Syndromes. Philadelphia, PA: W. B. Saunders; 2000: 1-46.
  2. Kojima S, Nakao S, Tomonaga M, et al. Consensus conference on the treatment of aplastic anemia. Int J Hematol. 2000;72: 118-123.
  3. Marsh JCW. Management of acquired aplastic anaemia. Blood Rev. 2005;19: 143-151. · DOI
  4. Nakao S, Feng X, Sugimori C. Immune pathophysiology of aplastic anemia. Intl J Hematol. 2005;82: 196-200. · DOI
  5. Young NS. Acquired aplastic anemia. In: Young NS, Gerson SL, High K, eds. Clinical Hematology. Philadelphia, PA: Elsevier; 2006: 136-157. · DOI
  6. Schrezenmeier H, Bacigalupo A. Aplastic Anemia: Pathophysiology and Treatment. Cambridge, United Kingdom: Cambridge University Press; 2000. · DOI
  7. Choudhry VP, Gupta S, Gupta M, Kashyap R, Saxena R. Pregnancy associated aplastic anemia: a series of 10 cases with review of literature. Hematolgy. 2002;7: 233-238. · DOI
  8. Lu J, Basu A, Melenhorst J, Young NS, Brown KE. Analysis of T-cell repertoire in hepatitis-associated aplastic anemia. Blood. 2004;103: 4588-4593. · DOI
  9. Morgan GJ, Alvares CL. Benzene and the hemopoietic stem cell. Chem Biol Interact. 2005;153-154: 217-222. · DOI
  10. Young NS. Drugs and chemicals. In: Young NS, Alter BP, eds. Aplastic Anemia, Acquired and Inherited. Philadelphia, PA: W. B. Saunders; 1994: 100-132.
  11. Gerson WT, Fine DG, Spielberg SP, Sensenbrenner LL. Anticonvulsant-induced aplastic anemia: increased susceptibility to toxic drug metabolites in vitro. Blood. 1983;61: 889-893. · DOI
  12. Sutton JF, Stacey M, Kearsey SE, et al. Increased risk for aplastic anemia and myelodysplastic syndrome in individuals lacking GSTT1 gene. Pediatric Blood Cancer. 2004;42: 122-126. · DOI
  13. Dufour C, Syahn J, Bacigalupo A, et al. Genetic polymorphisms of CYP3A4, GSTT1, GSTM1, GSTP1 and NQO1 and the risk of acquired idiopathic aplastic anemia in Caucasian patients. Haematologica. 2005;90: 1027-1031.
  14. Bacigalupo A. Aetiology of severe aplastic anaemia and outcome after allogeneic bone marrow transplantation or immunosuppression. Eur J Haematol. 1996;57(suppl 60): 16-19. · DOI
  15. Kaufman DW, Kelly JP, Levy M, Shapiro S. The Drug Etiology of Agranulocytosis and Aplastic Anemia. New York, NY: Oxford; 1991.
  16. Issaragrisil S, Kaufman D, Anderson T, et al. The epidemiology of aplastic anemia in Thailand. Blood. 2006;107: 1299-1307. · DOI
  17. Hirano N, Butler MO, von Bergwelt-Baildon MS, et al. Autoantibodies frequently detected in patients with aplastic anemia. Blood. 2003;102: 4567-4575. · DOI
  18. Feng X, Chuhjo T, Sugimori C, et al. Diazepam-binding inhibitor-related protein 1: a candidate autoantigen in acquired aplastic anemia patients harboring a minor populatoin of paroxysmal nocturnal hemoglobinuria-type cells. Blood. 2004; 104: 2425-2431. · DOI
  19. Hinterberger W, Rowlings PA, Hinterberger-Fischer M, et al. Results of transplanting bone marrow from genetically identical twins into patients with aplastic anemia. Ann Intern Med. 1997;126: 116-122. · DOI
  20. Young NS. Hematopoietic cell destruction by immune mechanisms in aquired aplastic anemia. Semin Hematol. 2000;37: 3-14. · DOI
  21. Sloand EM, Kim S, Maciejewski JP, et al. Intracellular interferon-γ in circulating and marrow T cells detected by flow cytometry and the response to imunosuppressive therapy in patients with aplastic anemia. Blood. 2002;100: 1185-1191. · DOI
  22. Risitano AM, Maciejewski JP, Green S, et al. Invivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. Lancet. 2004;364: 355-364. · DOI
  23. Maciejewski JP, Selleri C, Anderson S, Young NS. Fas antigen expression on CD34+ human marrow cells is induced by interferon-gamma and tumor necrosis factor-alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood. 1995;85: 3183-3190. · DOI
  24. Selleri C, Maciejewski JP, Sato T, Young NS. Interferon-γ constitutively expressed in the stromal microenviroment of human marrow cultures mediates potent hematopoietic inhibition. Blood. 1996; 87: 4149-4157. · DOI · Paper page
  25. Bloom ML, Wolk A, Simon-Stoos K, et al. A mouse model of human immune mediated bone marrow failure. Exp Hematol. 2004;32: 1163-1172. · DOI
  26. Chen J, Lipovsky K, Ellison FM, Calado RT, Young NS. Bystander destruction of hematopoietic progenitor and stem cells in a mouse model of infusion-induced bone marrow failure. Blood. 2004;104: 1671-1678. · DOI
  27. Chen J, Young NS. A murine model of bone marrow failure mediated by disparity in minor histocompatibility antigens [abstract]. Blood. 2004; 106: 12a. Abstract 132. · DOI
  28. Nakao S, Takamatsu H, Chuhjo T, et al. Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia. Blood. 1994;84: 4257-4261. · DOI
  29. Maciejewski JP, Follmann D, Rivera CE, et al. Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and PNH/aplastic anemia syndrome. Blood. 2001;98: 3513-3519. · DOI
  30. Peng J, Liu C, Zhu K, et al. The TNF2 allele is a risk factor to severe aplastic anemia independent of HLA-DR. Hum Immunol. 2003;64: 896-901. · DOI
  31. Demeter J, Messer G, Schrezenmeier H. Clinical relevance of the TNF-alpha promoter/enhancer polymorphism in patients with aplastic anemia. Ann Hematol. 2002;81: 566-569. · DOI
  32. Dufour C, Capasso M, Svahn J, et al. Homozygosis for (12) CA repeats in the first intron of the human IFN-gamma gene is significantly associated with the risk of aplastic anaemia in Caucasian population. Br J Haematol. 2004;126: 682-685. · DOI
  33. Gidvani V, Ramkissoon S, Wong E, et al. Tumor necrosis factor-alpha and interleukin-6 promoter gene polymorphisms in acquired bone marrow failure syndromes [abstract]. Proceedings of the 46th ASH Annual Meeting. 2004;104: 12b. Abstract 3707. · DOI
  34. Solomou EE, Keyvanfar K, Young NS. T-bet, a Th1 transcription factor, is up-regulated in T cells from patients with aplastic anemia. Blood. 2006; 107: 3983-3991. · DOI
  35. Xu JL, Nagasaka T, Nakashima N. Involvement of cytotoxic granules in the apoptosis of aplastic anaemia. Br J Haematol. 2003;120: 850-852. · DOI
  36. Zeng W, Kajigaya S, Chen G, et al. Transcript profile of CD4+ and CD8+ cells from the bone marrow of acquired aplastic anemia patients. Exp Hematol. 2004;32: 806-814. · DOI
  37. Poggi A, Negrini S, Zocchi MR, et al. Patients with paroxysmal nocturnal hemoglobinuria have a high frequency of peripheral-blood T cells expressing activating isoforms of inhibiting superfamily receptors. Blood. 2005;106: 2399-2408. · DOI
  38. Howe EC, Wlodarski M, Ball EJ, Rybicki L, Maciejewski JP. Killer immunoglobulin-like receptor genotype in immune-mediated bone marrow failure syndromes. Exp Hematol. 2005;33: 1357-1362. · DOI
  39. Maciejewski JP, Selleri C, Tadatsugu S, Anderson S, Young NS. A severe and consistent deficit in marrow and circulating primitive hematopoietic cells (long-term culture-initiating cells) in acquired aplastic anemia. Blood. 1996;88: 1983-1991. · DOI
  40. Schrezenmeier H, Jenal M, Herrmann F, Heimpel H, Raghavachar A. Quantitative analysis of cobblestone area-forming cells in bone marrow of patients with aplastic anemia by limiting dilution assay. Blood. 1996;88: 4474-4480. · DOI
  41. Philpott NJ, Scopes J, Marsh JCW, Gordon-Smith EC, Gibson FM. Increased apoptosis in aplastic anemia bone marrow progenitor cells: possible pathophysiologic significance. Exp Hematol. 1995;23: 1642-1648.
  42. Kakagianni T, Giannakoulas NC, Thanopoulou E, et al. A probable role for trail-induced apoptosis in the pathogenesis of marrow failure: implications from an in vitro model and from marrow of aplastic anemia patients. Leuk Res. 2006;30: 713-721. · DOI
  43. Zeng W, Chen G, Kajigaya S, et al. Gene expression profiling in CD34 cells to identify differences between aplastic anemia patients and healthy volunteers. Blood. 2004;103: 325-332. · DOI
  44. Zeng W, Miyazato A, Chen G, Kajigaya S, Young NS. Interferon-γ-induced gene expression in CD34 cells: identification of pathologic cytokine-specific signature profiles. Blood. 2006;107: 167-175. · DOI
  45. Ball SE, Gibson FM, Rizzo S, et al. Progressive telomere shortening in aplastic anemia. Blood. 1998;91: 3582-3592. · DOI
  46. Brummendorf TH, Maciejewski JP, Young NS, Lansdorp PL. Telomere length in leukocyte subpopulations of patients with aplastic anemia. Blood. 2001;97: 895-900. · DOI · Paper page
  47. Savage SA, Calado RT, Lansdorp PM, Chanock SJ, Young NS. Genetic variation in telomeric repeat binding factor 1 but not telomeric repeat binding factor 2 are associated with aplastic anemia. Exp Hematol. 2006;34: 664-671. · DOI · Paper page
  48. Thornley I, Dror Y, Sung L, Wynn RF, Freedman MH. Abnormal telomere shortening in leucocytes of children with Shwachman-Diamond syndrome. Br J Haematol. 2002;117: 189-192. · DOI
  49. Calado RT, Bruno T, Wilkerson KL, Young NS. Evidence for T-cell oligoclonal expansion in aplastic anemia associated with telomerase complex mutations: pathophysiological and clinical implications [abstract]. Blood. 2005;106: 307a. Abstract 1052. · DOI
  50. Young NS. Paroxysmal nocturnal hemoglobinuria: current issues in pathophysiology and treatment. Curr Hematol Rep. 2005;4: 103-109.
  51. Sugimori C, Chuhjo T, Feng X, et al. Minor population of CD55-CD59 blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood. 2006;107: 1308-1314. · DOI
  52. Takami A, Zeng W, Wang H, Matsuda T, Nakao S. Cytotoxicity against lymphoblastoid cells mediated by a T-cell clone from an aplastic anaemia patient: role of CD59 on target cells. Br J Haematol. 1999;107: 791-796. · DOI
  53. Karadimitris A, Notaro R, Koehne G, Roberts IAG, Luzzatto L. PNH cells are as sensitive to T-cell-mediated lysis as their normal counterparts: implications for the pathogenesis of paroxysmal nocturnal haemoglobinuria. Brit J Haematol. 2000;111: 1158-1163. · DOI
  54. Chen G, Kirby M, Zeng W, Young NS, Maciejewski JP. Superior growth of glycophosphatidy linositol-anchored protein-deficient progenitor cells in vitro is due to the higher apoptotic rate of progenitors with normal phenotype in vivo. Exp Hematol. 2002;30: 774-782. · DOI
  55. Chen G, Zeng W, Maciejewski JP, et al. Differential gene expression profile in hematopoietic progenitors form paroxysmal nocturnal hemoglobinuria patients reveals an apoptosis/immune response in `normal' phenotype cells. Leukemia. 2005;19: 862-868. · DOI
  56. Hanaoka N, Kawaguchi T, Horikawa K, et al. Immunoselection by natural killer cells of PIGA mutant cells missing stress-inducible ULBP. Blood. 2006;107: 1184-1191. · DOI
  57. Maciejewski JP, Selleri C. Evolution of clonal cytogenetic abnormalities in aplastic anemia. Leuk Lymphoma. 2004;45: 433-440. · DOI
  58. Sloand EM, Fuhrer M, Risitano A, et al. Preferential suppression of trisomy 8 versus normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood. 2005;106: 841-851. · DOI
  59. Sloand EM, Rezvani K, Mainwaring L, et al. Myelodysplasia with trisomy 8 is associated with a cytotoxic CD8 T cell immune response to Wilms tumor-1 protein (WT1) [abstract]. Blood. 2004; 104: 138a. Abstract 474. · DOI
  60. Sloand EM, Mainwaring L, Tarnowka MK, Barrett AJ, Young NS. CD34 cells from patients with trisomy 8 express early apoptotic markers but do not undergo programmed cell death because of upregulation of anti-apoptotic proteins [abstract]. Blood. 2003;102: 145a. Abstract 497.
  61. Maciejewski JP, Risitano AM, Nunez O, Young NS. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood. 2002;99: 3129-3135. · DOI
  62. Kojima S, Ohara A, Tsuchida M, et al. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood. 2002;100: 786-790. · DOI
  63. Sloand EM, Yong A, Solomou EE, et al. Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor. Proc Natl Acad Sci U S A. In press.
  64. Frickhofen N, Rosenfeld SJ. Immunosuppressive treatment of aplastic anemia with antithymocyte globuilin and cyclosporine. Semin Hematol. 2000; 37: 56-68. · DOI
  65. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmaier H. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood. 2003;101: 1236-1242. · DOI
  66. Bacigalupo A, Bruno B, Saracco P, et al. Antilymphocyte globuilin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients: European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood. 2000;95: 1931-1934. · DOI
  67. Rosenfeld S, Follman D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003;289: 1130-1135. · DOI
  68. Kojima S, Hibi S, Kosaka Y, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood. 2000;96: 2049-2054. · DOI
  69. Scheinberg P, Nunez O, Wu C, Young NS. Treatment of severe aplastic anaemia with combined immunosuppression: antithymocyte globulin, ciclosporin, and mycophenolate mofetil. Br J Haematol. 2006;133: 606-611. · DOI
  70. Marsh J, Schrezenmeier H, Marin P, et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anemia Working Party. Blood. 1999;93: 2191-2195. · DOI
  71. Raghavachar A, Kolbe K, Höffken K, et al. A randomized trial of standard immunosuppression versus cyclosporine and filgastrim in severe aplastic anemia [abstract]. Blood. 1997;90: 439a. Abstract 1951.
  72. Fuhrer M, Rampf U, Baumann I, et al. Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. Blood. 2005;106: 2102-2104. · DOI
  73. Fang JP, Xu HG, Huang SL, Chen C, Huang K. Immunosuppressive treatment of aplastic anemia in Chinese children with antithymocyte globulin and cyclosporine. Pediatr Hematol Oncol. 2006; 23: 45-50. · DOI
  74. Tichelli A, Socié G, Henry-Amar M, et al. Effectiveness of immunosuppressive therapy in older patients with aplastic anemia: The European Group for Blood and Marrow Transplantation Several Aplastic Anaemia Working Party. Ann Intern Med. 1999;130: 193-201. · DOI
  75. Tichelli A, Passweg J, Nissen C, et al. Repeated treatment with horse antilymphocyte globulin for severe aplastic anaemia. Br J Haematol. 1998; 100: 393-400. · DOI
  76. Scheinberg P, Nunez O, Young NS. Retreatment with rabbit anti-thymocyte globulin and cyclosporine for patients with relapsed or refractory severe aplastic anemia. Br J Haematol. 2006;133: 622-627. · DOI
  77. Socié G, Rosenfeld S, Frickhofen N, Gluckman E, Tichelli A. Late clonal diseases of treated aplastic anemia. Semin Hematol. 2000;37: 91-101. · DOI
  78. Jeng MR, Naidu PE, Rieman MD, et al. Granulocyte-macrophage colony stimulating factor and immunosuppression in the treatment of pediatric acquired severe aplastic anemia. Pediatr Blood Cancer. 2005;45: 170-175. · DOI
  79. Gluckman E, Rokicka-Milewska R, Hann I, et al. Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia. Br J Haematol. 2002;119: 1075-1082. · DOI
  80. Brodsky RA, Sensenbrenner LL, Smith BD, et al. Durable treatment-free remission after high dose cyclophosphamide therapy for previously severe aplastic anemia. Ann Intern Med. 2001;135: 477-483. · DOI
  81. Brodsky RA, Chen A, Dorr DM, Brodsky I, Jones RJ. High dose cyclophosphamide (CY) for severe aplastic anemia (SAA): safety and long term follow-up [abstract]. Blood. 2005;106: 41a-42a. Abstract 129. · DOI
  82. Tisdale JF, Dunn DE, Geller NL, et al. High-dose cyclophosphamide in severe aplastic anemia: a randomized trial. Lancet. 2000;356: 1554-1559. · DOI
  83. Tisdale JF, Maciejewski JP, Nunez O, Rosenfeld SJ, Young NS. Late complications following treatment for severe aplastic anemia (SAA) with high-dose cyclophosphamide (Cy): follow-up of a randomized trial. Blood. 2002;100: 4668-4670. · DOI
  84. Di Bona E, Rodeghiero F, Bruno B, et al. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Br J Haematol. 1999; 107: 330-334. (Erratum in: Br J Haematol. 2000; 108:461.) · DOI
  85. Gupta V, Gordon-Smith EC, Cook G, et al. A third course of anti-thymocyte globulin in aplastic anaemia is only beneficial in previous responders. Br J Haematol. 2005;129: 110-117. · DOI
  86. Howard SC, Naidu PE, Hu XJ, et al. Natural history of moderate aplastic anemia in children. Pediatr Blood Cancer. 2004;43: 545-551. · DOI
  87. Maciejewski JP, Sloand EM, Nunez O, Boss C, Young NS. Recombinant humanized anti-IL-2 receptor antibody (Daclizumab) produces responses in patients with moderate aplastic anemia. Blood. 2003;102: 3584-3586. · DOI
  88. Calado RT, Yewdell WT, Wilkerson KL, Kajigaya S, Young NS. Sex hormones up-regulate telomerase activity of normal human hematopoietic cells and restore telomerase activity in carriers of telomerase complex mutations [abstract]. Blood. 2005;106: 641a. Abstract 2276. · DOI
  89. Passweg JR, Perez WS, Eapen M, et al. Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia. Bone Marrow Transplant. 2006;37: 641-649. · DOI
  90. Reiter E, Keil F, Brugger S, et al. Excellent long-term survival after allogeneic marrow transplantation in patients with severe aplastic anemia. Bone Marrow Transplant. 1997;19: 1191-1196. · DOI
  91. Locatelli F, Bruno B, Zecca M, et al. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. Blood. 2000;96: 1690-1697.
  92. Kim I, Yoon SS, Park S, Kim BK, Kim NK. The treatment of severe aplastic anemia: outcomes of bone marrow transplantation and immunosuppressive therapy in a single institution of Korea. J Korean Med Sci. 2003;18: 365-371. · DOI
  93. Ahn MJ, Choi JH, Lee YY, et al. Outcome of adult severe or very severe aplastic anemia treated with immunosuppressive therapy compared with bone marrow transplantation: multicenter trial. Intl J Hematol. 2003;78: 133-138. · DOI
  94. Kröger N, Zabelina T, Renges H, et al. Long-term follow-up of allogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus antithymocyte globulin. Ann Hematol. 2002;81: 627-631. · DOI
  95. Ades L, Mary JY, Robin M, et al. Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood. 2004;103: 2490-2497. · DOI
  96. Dulley FL, Vigorito AC, Aranha FJP, et al. Addition of low-dose busulfan to cyclophosphamide in aplastic anemia patients prior to allogeneic bone marrow transplantation to reduce rejection. Bone Marrow Transplant. 2004;33: 9-13. · DOI
  97. Bai LY, Chiou TJ, Liu JH, et al. Hematopoietic stem cell transplantation for severe aplastic anemia: experience of an institute in Taiwan. Ann Hematol. 2004;83: 38-43. · DOI
  98. Abdelkefi A, Ben Othman T, Ladeb S, et al. Bone marrow transplantation for patients with acquired severe aplastic anemia using cyclophosphamide and antithymocyte globulin: the experience from a single center. Hematol J. 2003;4: 208-213. · DOI
  99. Kim HJ, Park CY, Park YH, et al. Successful allogeneic hematopoietic stem cell transplantation using triple agent immunosuppression in severe aplastic anemia patients. Bone Marrow Transplant. 2003;31: 79-86. · DOI
  100. Gupta V, Ball SE, Yi Q, et al. Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia. Biol Blood Bone Marrow Transplant. 2004;10: 867-876. · DOI
  101. Kahl C, Leisenring W, Deeg HJ, et al. Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up. Br J Haematol. 2005;130: 747-751. · DOI
  102. Storb R, Blume KG, O'Donnell MR, et al. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. Biol Blood Marrow Transplant. 2001;7: 39-44. · DOI
  103. Gomez-Almaguer D, Vela-Ojeda J, Jaime-Perez JC, et al. Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: the Mexican experience. Am J Hematol. 2006;81: 157-161. · DOI
  104. Horowitz MM. Current status of allogeneic bone marrow transplantation in acquired aplastic anemia. Semin Hematol. 2000;37: 30-42. · DOI
  105. Srinivasan R, Takahashi Y, McCoy JP, et al. Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation. Br J Haematol. 2006; 133: 305-314. · DOI
  106. Deeg HJ, Leisenring W, Storb R, et al. Long-term outcome after marrow transplantation for severe aplastic anemia. Blood. 1998;91: 3637-3645. · DOI
  107. Gupta V, Ball SE, Sage D, et al. Marrow transplants from matched unrelated donors for aplastic anaemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning. Bone Marrow Transplant. 2005;35: 467-471. · DOI
  108. Kojima S, Inaba J, Yoshimi A, et al. Unrelated donor marrow transplantation in children with severe aplastic anaemia using cyclophosphamide, anti-thymocyte globulin and total body irradiation. Br J Haematol. 2001;114: 706-711. · DOI
  109. Vassiliou GS, Webb DKH, Pamphilon D, Knapper S, Veys PA. Improved outcome of alternative donor bone marrow transplantation in children with severe aplastic anaemia using a conditioning regimen containing low-dose total body irradiation, cyclophosphamide and Campath. Br J Haematol. 2001;114: 701-705. · DOI
  110. Kojima S, Matsuyama T, Kato S, et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood. 2002;100: 799-805. · DOI
  111. Benesch M, Urban C, Sykora KW, et al. Transplantation of highly purified CD34+ progenitor cells from alternative donors in children with refractory severe aplastic anaemia. Br J Haematol. 2004;125: 58-63. · DOI
  112. Kang HJ, Shin HY, Choi HS, Ahn HS. Fludarabine, cyclophosphamide plus thymoglobulin conditioning regimen for unrelated bone marrow transplantation in severe aplastic anemia. Bone Marrow Transplant. 2004;34: 939-943. · DOI
  113. Mao P, Wang S, Wang S, et al. Umbilical cord blood transplant for adult patients with severe aplastic anemia using anti-lymphocyte globulin and cyclophosphamide as conditioning therapy. Bone Marrow Transplant. 2004;33: 33-38. · DOI
  114. Bacigalupo A, Locatelli F, Lanino E, et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant. 2005;36: 947-950. · DOI
  115. Bunin N, Aplenc R, Iannone R, et al. Unrelated donor bone marrow transplantation for children with severe aplastic anemia: minimal GVHD and durable engraftment with partial T-cell depletion. Bone Marrow Transplant. 2006;37: 143-149. · DOI
  116. Lee J-H, Choi S-J, Lee J-H, et al. Non-total body irradiation containing preparative regimen in alternative donor bone marrow transplantation for severe aplastic anemia. Bone Marrow Transplant. 2005;35: 755-761. · DOI
  117. Deeg HJ, O'Donnell M, Tolar J, et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood. 2006;108: 1485-1491. · DOI
  118. Deeg HJ, Seidel K, Casper J, et al. Marrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy. Biol Blood Marrow Transplant. 1999;5: 243-252. · DOI
  119. Margolis DA, Casper JT. Alternative-donor hematopoietic stem-cell transplantation for severe aplastic anemia. Semin Hematol. 2000;37: 43-55. · DOI
  120. Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med. 1997;339: 1565-1576. · DOI
  121. Woodard P, Cunningham JM, Benaim E, et al. Effective donor lymphohematopoietic reconstitution after haploidentical CD34+-selected hematopoietic stem cell transplantation in children with refractory severe aplastic anemia. Bone Marrow Transplant. 2004;33: 411-418. · DOI
  122. Bacigalupo A, Brand R, Oneto R, et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy: The European Group for Blood and Marrow Transplantation experience. Semin Hematol. 2000;37: 69-80. · DOI
  123. Ehrlich P. Ueber einem Fall von Anämie mit Bemerkungen über regenerative Veränderungen des Knochenmarks. Charité-Annalen. 1888;13: 300-309.

Cited by

See all 704

Metadata

Authors
Young, N. S., Calado, R. T., & Scheinberg, P.
Affiliations
From the Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Bethesda, MD.
Venue
Blood
Publisher
American Society of Hematology
Published
2006-10-15
Volume
108
Issue
8
Pages
2509-2519
ISSN
  • 0006-4971
  • 1528-0020
DOI
10.1182/blood-2006-03-010777
Cited by
704
References
3
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review